![]() |
Name |
Chrysogenolide D
|
Molecular Formula | C24H26O8 | |
IUPAC Name* |
(1R,2R,10S,13R,15R,18R,19R,21S)-19-hydroxy-7,7,13,18,21-pentamethylspiro[6,11,14,16-tetraoxahexacyclo[16.3.1.03,8.010,21.012,20.015,19]docosa-3,8,12(20)-triene-2,2'-oxirane]-5,17-dione
|
|
SMILES |
C[C@@H]1C2=C3[C@@]4([C@@H](C[C@@]5([C@]3([C@H](O1)OC5=O)O)C)[C@]6(CO6)C7=CC(=O)OC(C7=C[C@@H]4O2)(C)C)C
|
|
InChI |
InChI=1S/C24H26O8/c1-10-16-17-22(5)13(8-21(4)18(26)31-19(29-10)24(17,21)27)23(9-28-23)12-7-15(25)32-20(2,3)11(12)6-14(22)30-16/h6-7,10,13-14,19,27H,8-9H2,1-5H3/t10-,13-,14+,19-,21+,22-,23+,24+/m1/s1
|
|
InChIKey |
ZNOSJWPDZUFPQD-WBTZUOPNSA-N
|
|
Synonyms |
Chrysogenolide D; CHEMBL4166961
|
|
CAS | NA | |
PubChem CID | 139589817 | |
ChEMBL ID | CHEMBL4166961 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 442.5 | ALogp: | -0.6 |
HBD: | 1 | HBA: | 8 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.0 | Aromatic Rings: | 7 |
Heavy Atoms: | 32 | QED Weighted: | 0.45 |
Caco-2 Permeability: | -5.278 | MDCK Permeability: | 0.00000948 |
Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.017 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.982 |
30% Bioavailability (F30%): | 0.113 |
Blood-Brain-Barrier Penetration (BBB): | 0.908 | Plasma Protein Binding (PPB): | 84.02% |
Volume Distribution (VD): | 2.343 | Fu: | 16.54% |
CYP1A2-inhibitor: | 0.04 | CYP1A2-substrate: | 0.862 |
CYP2C19-inhibitor: | 0.524 | CYP2C19-substrate: | 0.683 |
CYP2C9-inhibitor: | 0.414 | CYP2C9-substrate: | 0.007 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.057 |
CYP3A4-inhibitor: | 0.62 | CYP3A4-substrate: | 0.869 |
Clearance (CL): | 2.065 | Half-life (T1/2): | 0.695 |
hERG Blockers: | 0.099 | Human Hepatotoxicity (H-HT): | 0.954 |
Drug-inuced Liver Injury (DILI): | 0.306 | AMES Toxicity: | 0.968 |
Rat Oral Acute Toxicity: | 0.949 | Maximum Recommended Daily Dose: | 0.824 |
Skin Sensitization: | 0.518 | Carcinogencity: | 0.645 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.59 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005627 | ![]() |
0.624 | D0KR9U | ![]() |
0.223 | ||
ENC003927 | ![]() |
0.532 | D06IIB | ![]() |
0.221 | ||
ENC002931 | ![]() |
0.531 | D0G6AB | ![]() |
0.221 | ||
ENC005628 | ![]() |
0.434 | D02QJH | ![]() |
0.218 | ||
ENC004709 | ![]() |
0.352 | D02JNM | ![]() |
0.216 | ||
ENC003925 | ![]() |
0.321 | D06AEO | ![]() |
0.215 | ||
ENC002987 | ![]() |
0.318 | D03ZZK | ![]() |
0.215 | ||
ENC002851 | ![]() |
0.315 | D0P0HT | ![]() |
0.214 | ||
ENC005189 | ![]() |
0.310 | D0D2TN | ![]() |
0.212 | ||
ENC005317 | ![]() |
0.310 | D04GJN | ![]() |
0.211 |